Researchers found that an experimental nasal treatment called intranasal foralumab may significantly reduce inflammation in the brains of people with Multiple System Atrophy (MSA), a rare neurodegenerative disorder. In a small Phase 2 clinical trial involving two patients, PET imaging showed a reduction of up to 35% in inflammatory markers in critical brain regions affected by MSA. This finding is particularly important as MSA currently has no approved disease-modifying treatments.

For individuals concerned about aging and neurodegenerative diseases, these results suggest that intranasal foralumab might offer a new avenue for addressing inflammation linked to conditions like MSA. Reducing inflammation in the brain could potentially lead to improvements in symptoms associated with neurodegenerative diseases, which often include movement difficulties and cognitive decline. While this study is preliminary, it highlights the importance of innovative approaches to treating neuroinflammation, which could benefit many people facing these challenges.

The evidence comes from early-stage research involving just two patients, so while the findings are promising, they are not yet conclusive. More extensive trials are needed to confirm these results and to better understand the therapy’s potential. Tiziana Life Sciences, the company behind foralumab, plans to continue testing this treatment in additional patients to validate the initial findings and explore its effectiveness further.

Source: globenewswire.com